No abstract available.
Keratoacanthoma*

No abstract available.
Keratoacanthoma* ; Pilomatrixoma*

No abstract available.
Animals ; Horns* ; Keratoacanthoma*

Keratoacanthoma is a benign neoplasm that develops as a protruding mass especially on the central part of face, We experienced a case of keratoacanthoma that developed on the nasal vestibule after the eradication of verruca vulgaris on the same site by surgical intervention 3 months before. We treated it with total excision and skin graft.
Keratoacanthoma* ; Skin ; Transplants ; Warts*

No abstract available.
Carcinoma, Basal Cell* ; Keratoacanthoma*

Keratoacanthoma is a rapidly growing tumor that has the tendency of spontaneous involution but it may persist for some times, continue to enlarge and may become invasive and destructive. Many modalities are available for the treatment of keratoacanthoma. Although excisional surgery is the treatment of choice, this can result in functional and cosmetic defects when large or strategically located lesions are treated. An effective nonsurgical treatment would be desirable in such cases. We report two cases with unusually large or facial keratoacanthoma treated with intralesional methotrexate. One case showed complete resolution over 6 injections and the other after 2 injections. We suggest that intralesional injection of methotrexate is a simple, effective, safe and inexpensive method for the treatment of large keratoacanthoma.
Injections, Intralesional ; Keratoacanthoma* ; Methotrexate*

Keratoacanthoma is the epidermal tumor characterized by the benign course such as rapid growth and spontaneous resolution. Rarely keratoacanthoma invades adjacent structures. Therefore, controversies have arisen about the biologic behavior whether keratoacanthoma is a benign tumor or a variant of low grade cutaneous squamous cell carcinoma. We report a case of the recurred keratoacanthoma at the nasal vestibule treated with the surgical excision and the reconstruction by local bilobed rotation flap in a 54-year old female whose final pathology was confirmed as well differentiated squamous cell carcinoma.
Carcinoma, Squamous Cell ; Female ; Humans ; Keratoacanthoma* ; Pathology

Keratoacanthoma is a rapidly growing tumor that histologically resembles squamous cell carcinoma. Surgical excision is a desirable therapeutic option, but several other treatment modalities are available. We report on two cases of keratoacanthoma that were treated with imiquimod 5% cream. Imiquimod was applied daily for the first 6 or 7 days, and then reduced to alternate days according to the tolerance and erythema severity of the patient. In both patients, the tumors fully regressed after five weeks of treatment.
Carcinoma, Squamous Cell ; Erythema ; Humans ; Keratoacanthoma*

A 63-year-old man had a huge verrucous protruding mass over the suprasternal area. The lesion enlarged rapidly over 3 mooths, and measured about 10×8 cm. The histologic finding of the biopsy specimen showed nests of squamous epithelium with central keratinization, infiltrating the dermis. The neoplasm was treated successfully with surgical excision.
Biopsy ; Dermis ; Epithelium ; Humans ; Keratoacanthoma* ; Middle Aged

Keratoacanthoma (KA) is a benign epidermal tumor, characterized by rapid and abundant growth, a tendency toward spontaneous regression and histopathologic similarity to squamous cell carcinoma (SCC). Because KA can be easily misdiagnosed as SCC, surgery is considered the treatment of choice. Recently, regression of KAs following application of 5% imiquimod cream (Aldara(R)) has been reported. We present 4 cases of KA treated with topical imiquimod, applied 3 to 4 times a week. Obvious improvement was observed after 4 to 6 weeks of application and the lesions were almost cleared leaving scars after 9 to 11 weeks. These results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported. We also suggest that lesions treated with imiquimod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment.
Aminoquinolines ; Biopsy ; Carcinoma, Squamous Cell ; Cicatrix ; Keratoacanthoma